Small-molecule inhibitors of PDE-IV and -VII in the treatment of respiratory diseases and chronic inflammation

Expert Opinion on Investigational Drugs

Volumn 16, Issue 10, 2007, Pages 1585-1599

  Vijayakrishnan, Lalitha ^a   Rudra, Sonali ^a   Eapen, Mathew S ^a   Dastidar, Sunanda ^a   Ray, Abhijit ^a  

^a RANBAXY LABORATORIES LTD   (India)

Author keywords

Asthma; COPD; PDE IV; PDE VII; Respiratory diseases

Indexed keywords

2 METHYL 5 NITROBENZENESULFONIC ACID DIMETHYLAMIDE; BENZOTHIADIAZINE DERIVATIVE; BMS 586853; CC 10004; CILOMILAST; GABAPENTIN; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; OGLEMILAST; ONO 6126; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE VII; PHOSPHODIESTERASE VII INHIBITOR; PURINE NUCLEOTIDE; PURINE NUCLEOTIDE DERIVATIVE; PYRIMIDINE NUCLEOTIDE; PYRIMIDINE NUCLEOTIDE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; ROFLUMILAST; ROLIPRAM; SPIROQUINAZOLINONE DERIVATIVE; SULFONAMIDE; THEOPHYLLINE; THIADIAZOLE DERIVATIVE; TOFIMILAST; TPI 1100; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 393059; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; PHOSPHODIESTERASE-7;

ALLERGIC RHINITIS; ALLODYNIA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BINDING AFFINITY; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; NAUSEA; NONHUMAN; RESPIRATORY TRACT DISEASE; REVIEW; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE ACTIVATION; VOMITING; ANIMAL; CHRONIC DISEASE; DRUG ANTAGONISM; INFLAMMATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; CHRONIC DISEASE; HUMANS; INFLAMMATION; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 35248887662     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.10.1585     Document Type: Review

References (53)

1. GIEMBYCZ MA: Phosphodiesterase 4 inhibitors and the treatment of asthma; where we are now and where do we go from here? Drugs (2000) 59:193-212.
2. GIEMBYCZ MA: Development status of second-generation PDE4 inhibitors forasthma and COPD: the story so far? Monaldi. Arch. Chest Dis. (2002) 57:48-64.
3. SCOTT AI, PERINI AF, SHERING PA, WHALLEY LJ: In-patient major depression: is rolipra as effective as apytriptyline? Eur. J. Clin. Pharmacol. (1991) 40(2):127-129.
4. LOSCO PE, EVANS EW, BARAT SA et al.: the toxicity of SCH 351591, a novel phosphodiesterase 4B inhibitor, in cynomolgus monkeys. Toxicol. Pathol. (2004) 32(3):295-308.
5. MECKLENBERG L, HEUSER A, JUENGLING T et al.: Mesentritis precedes vasculitis in the rat mesentry after subacute administration of a phosphodiesterase type 4 inhibitor. Toxicol. Lett. (2006) 163(1):54-64.
6. WALLACE DA, JOHNSTON LA, HUSTON E et al.: Identification and characterization of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterases gene. Mol. Pharmacol. (2005) 67:1920-1934.
7. HUSTON E, LUMB S, RUSSELL A et a;.: Molecular cloning and transient expression in COS cells of a novel human PDE4B cAMP specific phosphodiesterase HSPDE4B3. Biochem. J. (1997) 328(Part 2):549-558.
8. RENA G, BEGG F, ROSS A et al.: Molecular cloning, genomic positioning, promoter identification and characterization of the novel cAMP specific phosphodiesterase PDE4A10. Mol. Pharmacol. (2001) 59:995-1011.
9. JIN SL, CONTI M: Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses. Proc. Natl. Acad. Sci. USA (2002) 99(11):7628-7633.
10. LIPWORTH BJ: Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet (2005) 365(9454):167-175.
11. ROCQUE WJ, TAIN J, WISEMAN JS et al.: Human recombinant phosphodiesterase 4B2B binds (R) - rolipram at a single site with two affinities. Biochemistry (1997) 36(46):14250-14261.
12. BARNETTE MS, BARTUS JO, BURMAN M et al.: Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competetion for [3H] rolipram. binding. J. Biochem. Pharmacol. (1996) 51(7):949-956.
13. ROBICHAUD A, STAMATIOU PB, JIN SL et al.: Deletion of phoshodiesterase 4D in mice shortens α(2)-adrenoceptor mediated anesthesia, a behavioural correlate of emesis. J. Clin. Invest. (2002) 110(7):1045-1052.
14. LENHART SE, WEHRENS XHT, REIKEN S et al.: Phoshodiesterase 4D deficiency in the ryanodine receptor complex promotes heart failure and arrhythmias. Cell (2005) 123:25-35.
15. GIEMBYCZ MA: Phosphodiesterase-4 selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. (2005) 2:333-336.
16. RABE KF, BATEMAN ED, O'DONNEL D, WITTE S, BREDEBBROKER D, BETHKE TD: Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomized controlled trial. Lancet (2005) 366(9485):563-571.
17. SABINA AA. Roflumilast for the treatment of chronic obstructive pulmonary disease. Curr. Opin. Investig. Drugs (2006) 7(5):412-417.
18. LEICHTL S, SCHMID-WIRLITSCH C, BREDENBROKER D et al.: Dose-related efficacy of once-daily roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in asthma. Am. J. Respir. Crit. Care Med. (2002) 165(8)-A185.
19. VAN SCHALKWYK E, STRYDOM K, WILLIAMS Z et al.: Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J. Allergy Clin. Immunol. (2005) 116:292-298.
20. CHRISTENSEN SB, GUIDER A, FORSTER CJ et al.: 1,4-Cyclohcxanecarboxylates: potent and selective inhibitors of phosophodiesterasc 4 for the treatment of asthma. J. Med. Chem. (1998) 41(6):821-835.
21. COMPTON CH, CUBB J, NEIMAN R et al.: Cilomilast a selective PDE4 inhibitor for the treatment of patients with chronic obstructive pulmonary disease: a randomized dose ranging study. Lancet (2001) 358:265-270.
22. COMPTON C, EDELSON J, CEDAR E et al.: Cilomast (Ariflo) 15 mg bid safety in a 6-month clinical trial program. 97th American Thoracic Society Meeting. San Francisco, USA (18 - 23 May 2001).
23. GEIMBYCZ MA: An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Br. J. Clin. Pharmacol. (2006):1-15.
24. SCHAFER P: CC-10004: a novel PDE4 inhibitor with an improved therapeutic index. SMI Conference - Chronic Obstructive Pulmonary Disorders. London, UK (10-11 March 2004).
25. ROSEN J, MILLER W, HE M et al.: A novel PDE4 inhibitory agent with endothelial cell specific activity. Proc. Am. Assoc. Cancer Res. (2004) 45:(Abstract 2372).
26. KHOBZAOUI M, GUTKE HJ, BURNET M: Cc-10004. Curr. Opin. Investig. Drugs (2005) 6(5):518-525.
27. TAKEDA H, AL E: Pharmacological profile of Ono-6126, a novel phosphodiesterase 4 (PDE4) inhibitor. 98th International Conference of the American Thoracic Society. Atlanta, USA (17-22 May 2002).
28. FURUIE H, NAKAGAWA S, KAWASHIMA M, AL E: Suppressive effect of novel phosphodiesterase 4 (PDE4) inhibitor Ono-6126 on TNF-α release was increased after repeated oral administration in healthy Japanese subjects. Eur. Respir J. (2003) (Suppl. 45):(Abstract 2557).
29. VAKKALANKA S: The pharmacological and safety profile of the PDE4 inhibitor GRC-3886. 14th Annual European Respiratory Society Congress. Glasgow, UK (4-8 September 2004).
30. DUPLANTIER AJ, BACHERT EL, CHENG CB et al.: SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]- 1,2,4-triazolo[4,3-α]pyridines as potent inhibitors of human eosinophil phosphodiesterase. J. Med. Chem. (2007) 50(2):344-349.
31. DRAHEIM R, EGERLAND U, RUNDFELDT C: Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl) -5-hydroxy-indole-3-yl]- glyoxylic acid amide (AWD 12-281), in human cell preparations. J. Pbarmacol. Exp. Ther. (2004) 308(2):555-563.
32. HANS-JURGEN G, JAN-HINRICH G, MOUSSA K, THEJAVATHI RG, MICHAEL B: AWD-12-281 (inhaled) elbion/GlaxoSmithKline. Curr. Opin. Investig. Drugs (2005)6(11):1149-1158.
33. MICHAELI T, BLOOM TG, MARTINS T et al.: Isolation and characterizaton of a previously undetected cAMP specific phosphodiesterase by complcmentation of a cAMP phosphodiesterase deficient Saccharomyces cerevisiae. J. Biol. Chem. (1993) 268:12925-12932.
34. HAN P, ZHU XY, MICHAELI T: Alternative splicing of the high affinity cAMP specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J. Biol. Chem. (1997). 272:16152-16157.
35. HETMAN JM, SODERLING SH, GLAVAS NA, BEAVO JA: 1. Cloning and characterization of PDE7B, a cAMP specific phosphodiesterasc. Proc. Natl. Acad. Sci. USA (2000) 97:472-476.
36. GIEMBYCZ MA, CORRIGAN CJ, SEYBOLD J, NEWTON R, BARNES PJ: Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4 and CD8 T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol. (1996) 118:1945-1958.
37. LI L, YEE C, BEAVO JA: CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science (1999) 283(5403):848-851.
38. YANG G, MCINTYRE KW, TOWNSEND RM et al.: Phosphodiesterase 7A-deficient mice have functional T cells. J. Immunol. (2003) 171(12):6414-6420.
39. + T-lymphocytes. Mol. Pharmacol. (2004) 66(6):1679-1689.
40. PITTS WJ, VACCARO W, HUYNH T et al.: Identification of purine inhibitors of phosphodiesterase 7 (PDE7). Bioorg. Med. Chem. Lett. (2004) 14:2955-2958.
41. KEMPSON J, MARINIER A, DODIER M et al.: Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and structure-activity relationships. Bioorg. Med. Chem. Lett. (2005) 15:1829-1833.
42. GUO J, CARLSEN M, BARBOSA J: Identification and SAR of potent inhibitors of phosphodiesterase 7 (PDE7). 228th ACS Meeting. Philadelphia, USA (22 - 26 August 2004).
43. BARNES MJ, COOPER N, DAVENPORT RJ et al.: Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. Bioorg. Med. Chem. Lett. (2001) 11(8):1081-1083.
44. MARTINEZ A, CASTRO A, GIL C et al.: Benzyl derivatives of 2,1,3-benzo-and benzothicno [3,2-a] thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors. J. Med. Chem. (2000) 43:683-689.
45. CASTRO A, ABASOLO MI, GIL C, SEGARRA V, MARTINEZ A: CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno [3,2-α] thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. Eur. J. Med. Chem. (2001) 36:333-338.
46. VERGNE F, BERNARDELLI P, LORTHIOIS E et al.: Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. 1. Design, synthesis and structure-activity relationship studies. Bioorg. Med. Chem. Lett. (2004) 14:4607-4613.
47. VERGNE F, BERNARDELLI P, LORTHIOIS E et al.: Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. 2. Metabolism directed optmization studies towards orally bioavailable derivatives. Bioorg. Med. Chem. Lett. (2004) 14:4615-4621.
48. LORTHIOIS E, BERNARDELLI P, VERGNE F et al.: Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1. Bioorg. Med. Chem. Lett. (2004) 14:4623-4626.
49. BERNARDELLI P, LORTHIOIS E, VERGNE F et al.: Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2. Optimization of 5,8-disubstituted derivatives. Bioorg. Med. Chem. Lett. (2004) 14:4627-4631.
50. HUNT H: A novel class of PDE inhibitors. Trends Med. Chem. (2000).
51. BROVIN H: IDDB Meeting Report Trends in medicinal chemistry - SMR symposium-Glaxo Wellcome Research & Development,Stevenage UK. (30 November 2000).
52. YAMAMOTO S, SUGAHARA S, IKEDA K, SHIMIZU Y. Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models. Eur. J. Pharm. (2006) 550(1-3):166-172.
53. YAMAMOTO S, SUGAHARA S, NAITO R et al.: The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo. Eur. J. Pharm. (2006) 541(1-2):106-114.